Why The 0.25mg Starter Dose Is Essential When Switching
Understanding Your Switch From Mounjaro To Wegovy Starter Requirements
When switching from Mounjaro to Wegovy, patients must begin with the 0.25mg starter dose regardless of their previous tirzepatide dose level. This isn't a step backwards - it's a clinical safety requirement reflecting the different receptor mechanisms between these prescription-only medicines. Mounjaro (tirzepatide) targets both GIP and GLP-1 receptors, while Wegovy (semaglutide) works exclusively on GLP-1 receptors.
The starter dose protocol ensures your body adapts to semaglutide's distinct pharmacological profile safely. Even patients maintained on Mounjaro 15mg must restart at Wegovy 0.25mg, following the complete 16-week escalation schedule. This approach minimises gastrointestinal side effects and optimises long-term tolerance when switching from Mounjaro to Wegovy treatment pathways.
Wegovy Starter Dose Pricing And Bundle Options For New Patients
EverydayMeds offers the Wegovy 0.25mg starter pen for £79.99, with new customers applying code FIRST40 at checkout to reach this price. Our Intro Duo bundle combines your first two doses (0.25mg and 0.5mg) for £169.99, providing seamless progression through weeks 1-8 of treatment. Returning customers benefit from code DOSE25 for ongoing prescription fills.
For patients planning extended treatment, our Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99 and covers your first 12 weeks when switching from Mounjaro to Wegovy. These bundles offer convenience rather than savings - ensuring uninterrupted supply whilst you adapt to your new medication. All orders include next-day temperature-controlled delivery through our GPhC-registered pharmacy service (#9012878).
Clinical Evidence Supporting Wegovy In Weight Management
The STEP clinical trial programme demonstrates Wegovy's efficacy in long-term weight management. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 2 showed 9.6% weight reduction in patients with type 2 diabetes.
The SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events (HR 0.80) among patients receiving semaglutide. When switching from Mounjaro to Wegovy, patients can expect similar appetite suppression and satiety enhancement, though individual responses may vary between the different receptor mechanisms.
How Wegovy's GLP-1 Mechanism Differs From Mounjaro
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your natural incretin hormone GLP-1. It reduces appetite by acting on brain appetite centres, promotes feelings of fullness after smaller meals, and may reduce food cravings throughout the day. Unlike Mounjaro's dual GIP/GLP-1 approach, Wegovy focuses exclusively on GLP-1 pathways for weight management. This targeted mechanism often produces different side effect profiles and appetite control patterns compared to tirzepatide treatment.
Simple Ordering Process For Switching Patients
Beginning your switch from Mounjaro to Wegovy takes just three minutes through our online clinical assessment. Our prescribers review your medical history, current medications, and switching rationale within three working days (express 24-hour service available). Once approved, your 0.25mg starter pen ships via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements. The assessment covers your previous Mounjaro experience, any side effects encountered, and ensures appropriate clinical oversight for your transition.
Storage Advantages And Practical Considerations
Wegovy offers superior travel flexibility with 6-week room temperature storage (below 30°C) compared to Mounjaro's 21-day limit. The FlexTouch pen delivers consistent dosing through its pre-filled, single-use design. Store unopened pens in your fridge at 2-8°C, and never freeze or shake the medication. The 16-week dose escalation cannot be abbreviated - each dose level serves specific therapeutic and tolerance-building purposes. Inject once weekly, same day each week, with or without food.
Transitioning Timeline And Washout Considerations
Most prescribers recommend a direct switch from Mounjaro to Wegovy without washout periods, starting your 0.25mg dose approximately one week after your final tirzepatide injection. This timing maintains therapeutic continuity whilst allowing receptor readjustment to semaglutide's selective GLP-1 action. Some patients experience different appetite patterns during the first 2-4 weeks as their system adapts to the new medication profile.
Your previous Mounjaro dose level doesn't influence your Wegovy starting dose - all patients begin at 0.25mg for clinical safety. The transition period may involve temporary changes in appetite control or gastrointestinal tolerance as your body adjusts to semaglutide's mechanism compared to tirzepatide's dual-receptor approach.
Long-term Management After Successfully Switching
Patients switching from Mounjaro to Wegovy often maintain similar weight management outcomes once they reach therapeutic doses around week 17. The 2.4mg maintenance dose provides sustained appetite control and supports continued weight management alongside reduced-calorie diet and increased physical activity. Regular monitoring ensures optimal dosing and identifies any adjustment needs during your transition period.
Both medications require long-term commitment - STEP trial extensions showed patients regained approximately two-thirds of lost weight within one year of stopping treatment. When switching from Mounjaro to Wegovy, focus on sustainable lifestyle changes that complement your new medication's appetite-suppressing effects for lasting success.
Start Your Wegovy Journey Today
Ready to begin switching from Mounjaro to Wegovy? Order your 0.25mg starter dose for £79.99 with new customer code FIRST40 applied at checkout. Our clinical team provides ongoing support throughout your transition, ensuring safe and effective treatment continuation. Complete your assessment today and receive your prescription-only medicine via next-day delivery from our MHRA-regulated facility. Trust EverydayMeds for professional weight management support backed by clinical expertise and pharmaceutical excellence.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
